IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+43.34%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$350M
AUM Growth
+$350M
(+8.8%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
3.22%
Top 10 Holdings %
Top 10 Hldgs %
41.9%
Holding
166
New
42
Increased
21
Reduced
58
Closed
16
Top Buys
| 1 |
Scholar Rock
SRRK
|
$15.4M |
| 2 |
Forte Biosciences
FBRX
|
$13.8M |
| 3 |
TG Therapeutics
TGTX
|
$8.77M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$7.36M |
| 5 |
Vir Biotechnology
VIR
|
$6.59M |
Top Sells
| 1 |
Tarsus Pharmaceuticals
TARS
|
$23.4M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.2M |
| 3 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$5.76M |
| 4 |
Arcus Biosciences
RCUS
|
$5.44M |
| 5 |
Capricor Therapeutics
CAPR
|
$4.56M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sarepta Therapeutics
SRPT
$1.98B
| $4.14M | 0.56% |
34,087
-20,089
| -37% | -$2.44M |
|
27
Evolus
EOLS
$477M
| $4.12M | 0.56% |
373,265
+114,986
| +45% | +$1.27M |
|
28
Mineralys Therapeutics
MLYS
$1.94B
| $4.09M | 0.56% |
332,390
+152,390
| +85% | +$1.88M |
|
29
Nuvalent
NUVL
$5.74B
| $4.09M | 0.56% |
52,216
-22
| -0% | -$1.72K |
|
30
Janux Therapeutics
JANX
$1.38B
| $4M | 0.54% |
+74,691
| New | +$4M |
|
|
VRNA
31
Verona Pharma
VRNA
$9.18B
| $3.72M | 0.51% |
+80,000
| New | +$3.72M |
|
|
CYBN
32
Cybin
CYBN
$142M
| $3.5M | 0.48% |
397,175
+29,980
| +8% | +$264K |
|
33
Arcturus Therapeutics
ARCT
$467M
| $3.39M | 0.46% |
+200,000
| New | +$3.39M |
|
34
Lexeo Therapeutics
LXEO
$266M
| $3.29M | 0.45% |
499,301
+242,085
| +94% | +$1.59M |
|
35
Abeona Therapeutics
ABEO
$356M
| $2.97M | 0.4% |
533,581
-50,012
| -9% | -$279K |
|
36
Relay Therapeutics
RLAY
$709M
| $2.86M | 0.39% |
693,308
-42
| -0% | -$173 |
|
37
Rocket Pharmaceuticals
RCKT
$358M
| $2.79M | 0.38% |
221,911
+24,815
| +13% | +$312K |
|
38
Protagonist Therapeutics
PTGX
$3.62B
| $2.7M | 0.37% |
+70,000
| New | +$2.7M |
|
39
Aligos Therapeutics
ALGS
$75.1M
| $2.56M | 0.35% |
+64,300
| New | +$2.56M |
|
40
Zevra Therapeutics
ZVRA
$501M
| $2.44M | 0.33% |
+292,772
| New | +$2.44M |
|
41
Xenon Pharmaceuticals
XENE
$2.99B
| $2.43M | 0.33% |
62,052
-45,135
| -42% | -$1.77M |
|
42
Ventyx Biosciences
VTYX
$184M
| $2.39M | 0.33% |
1,092,590
+899,943
| +467% | +$1.97M |
|
|
OKUR
43
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $2.18M | 0.3% |
253,754
+151,187
| +147% | +$1.3M |
|
44
Monte Rosa Therapeutics
GLUE
$309M
| $2.16M | 0.29% |
311,575
-18
| -0% | -$125 |
|
|
SLRN
45
DELISTED
ACELYRIN
SLRN
| $2.12M | 0.29% |
676,608
-466
| -0.1% | -$1.46K |
|
46
Cardiff Oncology
CRDF
$130M
| $1.95M | 0.27% |
+450,000
| New | +$1.95M |
|
47
Sangamo Therapeutics
SGMO
$161M
| $1.9M | 0.26% |
+1,860,179
| New | +$1.9M |
|
48
Nektar Therapeutics
NKTR
$543M
| $1.89M | 0.26% |
135,269
+47,775
| +55% | +$666K |
|
49
Protara Therapeutics
TARA
$125M
| $1.85M | 0.25% |
350,489
+194,777
| +125% | +$1.03M |
|
50
Alector
ALEC
$282M
| $1.8M | 0.24% |
+950,000
| New | +$1.8M |
|